Cancers in the proximal colon, distal colon, and rectum are frequently studied together; however, there are biological differences in cancers across these sites, particularly in the prevalence of microsatellite instability.
We assessed the differences in survival by colon or rectal cancer site, considering the contribution of microsatellite instability to such differences.
This is a population-based prospective cohort study for cancer survival.
This study was conducted within the Colon Cancer Family Registry, an international consortium. Participants were identified from population-based cancer registries in the United States, Canada, and Australia.
Information on tumor site, microsatellite instability, and survival after diagnosis was available for 3284 men and women diagnosed with incident invasive colon or rectal cancer between 1997 and 2002, with ages at diagnosis ranging from 18 to 74.
Cox regression was used to calculate hazard ratios for the association between all-cause mortality and tumor location, overall and by microsatellite instability status.
Distal colon (HR, 0.59; 95% CI, 0.49–0.71) and rectal cancers (HR, 0.68; 95% CI, 0.57–0.81) were associated with lower mortality than proximal colon cancer overall. Compared specifically with patients with proximal colon cancer exhibiting no/low microsatellite instability, patients with distal colon and rectal cancers experienced lower mortality, regardless of microsatellite instability status; patients with proximal colon cancer exhibiting high microsatellite instability had the lowest mortality.
Study limitations include the absence of stage at diagnosis and cause-of-death information for all but a subset of study participants. Some patient groups defined jointly by tumor site and microsatellite instability status are subject to small numbers.
Proximal colon cancer survival differs from survival for distal colon and rectal cancer in a manner apparently dependent on microsatellite instability status. These findings support the premise that proximal colon, distal colon, and rectal cancers are clinicopathologically distinct.
See related article on p. 935
1 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
2 Department of Epidemiology, University of Washington, Seattle, Washington
3 Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota
4 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Parkville, Victoria, Australia
5 Department of Medicine, University of North Carolina, Chapel Hill, North Carolina
6 Cancer Care Ontario, Toronto, Ontario, Canada
Funding/Support: This work was supported by the National Cancer Institute, National Institutes of Health (RFA CA-95-011) and through cooperative agreements with members of the Colon Cancer Family Registry and Principal Investigators. Collaborating centers include the Australian Colorectal Cancer Family Registry (5U24CA097735, M.A.J., A.K.W.), the Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (5U24CA074800, N.M.L.), the Ontario Registry for Studies of Familial Colorectal Cancer (5U24CA074783, S.G., R.G.), the Seattle Colon Cancer Family Registry (5U24CA074794, P.A.N.), and the University of Southern California (5U24CA074799, J.A.B.). This publication was also supported by National Cancer Institute career grant K05CA152715 (to P.A.N.) and training grant R25CA94880 (to A.I.P.).
Financial Disclosures: None reported.
Disclaimers: The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the C-CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the C-CFR.
Correspondence: Amanda I. Phipps, Ph.D., Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M4-B402, Seattle, WA 98109. E-mail: firstname.lastname@example.org